• María Dolores Corral Sánchez, Lucía Fernández Casanova, and Antonio Pérez-Martínez.
• Servicio de Hemato-Oncología Pediátrica, Hospital Universitario La Paz, Madrid, España.
• Med Clin (Barc). 2020 Feb 28; 154 (4): 134-141.

AbstractChildren and adolescents suffering from refractory leukaemia, relapse after stem cell transplantation, solid metastatic tumour or refractory to conventional treatments still condition a dismal prognosis. The critical role of the immune system in the immunosurveillance of cancer is becoming relevant with the development of new treatments such as the checkpoint inhibitor drugs and genetic modified T lymphocytes, tisagenlecleucel or axicabtagene ciloleucel. In addition, other immunotherapies are being developed such as cell therapy with natural killer (NK) lymphocytes. The rapid and potent cytotoxic activity of NK cells respecting healthy cells and the possibility of expansion, manipulating them and combining them with other treatments, make these cells a powerful therapeutic tool to be developed, with a very high safety profile. Furthermore, new strategies are being developed to increase the therapeutic benefit of NK cells such as genetic manipulation for the expression of chimeric antigen receptors.Copyright © 2019 Elsevier España, S.L.U. All rights reserved.

20 keywords...

hide…